Literature DB >> 1464147

Exposure and health assessment during application of lambda-cyhalothrin for malaria vector control in Pakistan.

G Chester1, N N Sabapathy, B H Woollen.   

Abstract

Icon 10 WP insecticide, a wettable powder formulation containing 10% lambda-cyhalothrin, was evaluated for possible adverse effects on the health of spraymen and villagers during treatment of dwellings for malaria vector control. Skin sensory effects and occasional coughing and sneezing in confined spaces were the only symptoms noted by the workers resulting from the handling and spraying of the insecticide. Absorption of lambda-cyhalothrin was estimated by determining its metabolites in urine and serum. The average amount of lambda-cyhalothrin absorbed by the workers per day (54 micrograms) represents less than 0.0001% (< 1 micrograms.kg-1.day-1) of the average daily amount of the substance handled. Only a small proportion of villagers showed detectable levels of lambda-cyhalothrin metabolites in their urine. Absorption of lambda-cyhalothrin from the formulation tested was therefore very low and, apart from the nuisance of skin sensory effects, there should be no risk to the health of workers or to the villagers whose dwellings are treated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464147      PMCID: PMC2393370     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

1.  Human dose-excretion studies with the pyrethroid insecticide, cypermethrin.

Authors:  C V Eadsforth; M K Baldwin
Journal:  Xenobiotica       Date:  1983-02       Impact factor: 1.908

  1 in total
  1 in total

1.  Excretion time courses of lambda-cyhalothrin metabolites in the urine of strawberry farmworkers and effect of coexposure with captan.

Authors:  Yélian Marc Bossou; Jonathan Côté; Louiza Mahrouche; Marc Mantha; Naïma El Majidi; Alexandra Furtos; Michèle Bouchard
Journal:  Arch Toxicol       Date:  2022-05-14       Impact factor: 6.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.